A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis

References

• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
   PubMed Web of Science ®Google Scholar
• Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest. 2007;132(4):1311–1321.
   PubMed Web of Science ®Google Scholar
• Raghu G, Anstrom KJ, King TE, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–1977.
   PubMed Web of Science ®Google Scholar
• Di Sario A, Bendia E, Svegliati Baroni G, et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol. 2002;37(5):584–591.
   PubMed Web of Science ®Google Scholar
• Hewitson T, Kelynack K, Tait M, et al. Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol. 2001;14(6):453–460.
   PubMed Web of Science ®Google Scholar
• Lin X, Yu M, Wu K, et al. Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon’s fibroblasts in vitro. Invest Ophthalmol Vis Sci. 2009;50(8):3763–3770.
   PubMed Web of Science ®Google Scholar
• Lee B, Margolin SB, Nowak R. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab. 1998;83(1):219–223.
   PubMed Web of Science ®Google Scholar
• FDA. FDA briefing document for New Drug Application (NDA) 22-535: Esbriet (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce the decline in lung function. Advisory Committee Meeting; 2010 Mar 9 [cited 2016 Feb 22]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM203081.pdf
   Google Scholar
• Rubino CM, Bhavnani SM, Ambrose PG, et al. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther. 2009;22(4):279–285.
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):821–829.
   PubMed Web of Science ®Google Scholar
• Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med. 1999;159:1061–1069.
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–1769.
   PubMed Web of Science ®Google Scholar
• King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092.
   PubMed Web of Science ®Google Scholar
• du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(4):459–466.
   PubMed Web of Science ®Google Scholar
• Jiang C, Huang H, Liu J, et al. Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials. PLoS One. 2012;7(10):e47024.
   PubMed Web of Science ®Google Scholar
• Ogura T, Azuma A, Inoue Y, et al. All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respir Investig. 2015;53(5):232–241.
   PubMedGoogle Scholar
• Kreuter M. Pirfenidone: an update on clinical trial data and insights from everyday practice. Eur Respir Rev. 2014;23(131):111–117.
   PubMedGoogle Scholar
• Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015;24(135):58–64.
   PubMed Web of Science ®Google Scholar
• Maher T, Cottin V, Skoeld M, et al. Pirfenidone post-authorisation safety registry (PASSPORT)-interim analysis of IPF treatment. Thorax. 2014;69(Suppl 2):A8–A9.
   Web of Science ®Google Scholar
• Alhamad EH. Pirfenidone treatment in idiopathic pulmonary fibrosis: a Saudi experience. Ann Thorac Med. 2015;10(1):38–43.
   PubMed Web of Science ®Google Scholar
• Arai T, Inoue Y, Sasaki Y, et al. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir Investig. 2014;52(2):136–143.
   PubMedGoogle Scholar
• Bonella F, Wessendorf TE, Costabel U. Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis. Dtsch Med Wochenschr. 2013 Mar;138(11):518–523. European Respiratory Society Annual Congress; 2013; Abstract 2548.
   Google Scholar
• Chaudhuri N, Duck A, Frank R, et al. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med. 2014;108(1):224–226.
   PubMed Web of Science ®Google Scholar
• Nieto A, Valenzuela C, Rivera I, et al. Pirfenidone in idiopathic pulmonary fibrosis (IPF): Spanish experience with the European named patient program (npp) and Spanish patient program (spp). Am J Respir Crit Care Med. 2014;189:A1418.
   Google Scholar
• Oltmanns U, Kahn N, Palmowski K, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration. 2014;88(3):199–207.
   PubMed Web of Science ®Google Scholar
• Okuda R, Hagiwara E, Baba T, et al. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med. 2013;107(9):1431–1437.
   PubMed Web of Science ®Google Scholar
• Ravaglia C, Gurioli C, Romagnoli M, et al. Pirfenidone treatment in idiopathic pulmonary fibrosis: an Italian case series. Eur Respir J. 2013;42(Suppl. 57):3370.
   Google Scholar
• Wijsenbeek MS, Grutters JC, Wuyts WA. Early experience of pirfenidone in daily clinical practice in Belgium and The Netherlands: a retrospective cohort analysis. Adv Ther. 2015;32(7):691–704.
   PubMed Web of Science ®Google Scholar
• Taniyama M, Ohbayashi S, Narita M, et al. Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients. Eur J Clin Pharmacol. 1997;52:77–78.
   PubMed Web of Science ®Google Scholar
• Aravena C, Labarca G, Venegas C, et al. Pirfenidone for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. PLoS One. 2015;10(8):e0136160.
   PubMed Web of Science ®Google Scholar
• Mandapalli P, Labala S, Bojja J, et al. Effect of pirfenidone delivered using layer-by-layer thin film on excisional wound healing. Eur J Pharm Sci. 2016;83:166–174.
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Guha R, Trivedi R, et al. Pirfenidone nanoparticles improve corneal wound healing and prevent scarring following alkali burn. PLoS One. 2013;8(8):e70528.
   PubMed Web of Science ®Google Scholar
• Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther. 2014;31(4):375–391.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–1087.
   PubMed Web of Science ®Google Scholar
• Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Albera C, Bradford WZ, et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax. 2016;71:429–435.
   PubMed Web of Science ®Google Scholar
• Roche H-L. Safety and tolerability of pirfenidone in combination with nintedanib in participants with idiopathic pulmonary fibrosis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2016 Feb 22]. Available from: https://clinicaltrials.gov/show/NCT02598193. NLM Identifier NCT02598193.
   Google Scholar
• Grupo Medifarma. Pirfenidone in the chronic hypersensitivity pneumonitis treatment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2016 Feb 22]. Available from: https://clinicaltrials.gov/show/NCT02496182. NLM Identifier NCT02496182.
   Google Scholar
• Rigshospitalet. European trial of pirfenidone in BOS, a European multi-center study (EPOS). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2016 Feb 22]. Available from: https://clinicaltrials.gov/show/NCT02262299. NLM Identifier NCT02262299.
   Google Scholar
• Beijing Continent Pharmaceutical Co, LTD. Safety and efficacy study of pirfenidone to treat Grade 2 or above radiation-induced lung injury. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2016 Feb 22]. Available from: https://clinicaltrials.gov/show/NCT02296281. NLM Identifier NCT02296281.
   Google Scholar
• Genentech, Inc. Safety and tolerability of pirfenidone in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) (LOTUSS). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2016 Feb 22]. Available from: https://clinicaltrials.gov/show/NCT01933334. NLM Identifier NCT01933334.
   Google Scholar